דברי פתיחה - ד"ר וילי מרמלשטיין
Surgical Considerations in the Treatment of Residual Disease When and to Whom? Prof. Jack Baniel (Bellinson MC)
Debate: House believes - Surgery is the best Treatment option in the High-Risk Prostate Cancer. Prof. Ilan Leybovich (Meir MC)
Decision making in the treatment paradigm in Advanced Lines of mRCC. The Expert Insight Prof. Manuela Shmidinger (Sponsored by Medison)
Debate: House believes - Radiation Therapy combined with Hormonal Treatment is the Best Treatment Option in High-Risk Prostate Cancer. Prof. Eliahu Gez (Tzfat MC)
Debate: HSPC. House believes - Abiraterone Acetate Combined with ADT is the Best First Line Treatment Option. Dr. Steve Frank.(Hadassa MC)
Debate: HSPC. House believes - Docetaxel Combined with ADT is the Best First Line Treatment Option. Dr. Raya Leibovich (Sheba MC)
Debate – Management of Stage IIA-IIB Seminoma. House believes - Radiation Therapy is Preferred Option. Dr. Marc Wygoda (Hadassa MC)
Value and Timing of High-dose chemotherapy with Autologous Stem Cell Rescue in the Failure of Previous Treatment. Dr. Daniel Goldshtein (Bellinson MC)
Invited Lecture – Navigation in Multiple Genomic Tests – What the Oncologist Should Know. Dr. Gilad Vainer, (Institute of Pathology, Sourasky MC)
Debate - Management of Stage IIA-IIB Seminoma. House believes - Chemotherapy is Preferred Option. Dr. Avivit Noiman (Rambam MC)
Updates in the management of Castrate – Resistant Prostate Cancer (CRPC). Dr. Avivit Peer (Rambam MC) (Sponsored by Astellas)
Challenging Case Presentations – Prof. Avishay Sella (Asaf Harofe) and Dr. Michal Sarfaty (Bellinson MC)
First-Line Chemotherapy for High-Risk GCT: Do We Need Dose Intensification? Prof. Avishay Sella (Asaf Harofe MC)
Long-term Health Outcomes of Germ Cell Tumor Survivors. Dr. Willy Mermelshtein (Soroka MC)
Results of POUT Study – Is It a New Standard of Care in Upper-Tract Urothelial Carcinoma? Dr. Noa Shani Shrem (Soroka MC)
Current Dilemmas in the Choice of First Line Treatment in mUC. Dr. Michal Sarfaty (Bellinson MC) (Sponsored by Roche)
mUC & Predictors of Response to IO agents. Dr. David Sarid (Sourasky MC) (Sponsored By A-Z)